Monoclonal antibody aiming at immune checkpoint molecule CD276 and application thereof

By developing monoclonal antibodies 2B2-1 and 5G4-2 with well-defined sequences, the problems of undisclosed sequences, poor cross-species reactivity, and inconsistent detection platforms of existing anti-B7-H3 antibodies have been solved. These antibodies achieve high specificity and high affinity, enhance the killing ability of T cells against CD276-overexpressing tumor cells, and promote the development of CD276-targeted diagnosis and treatment.

CN122255276APending Publication Date: 2026-06-23THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
0 Cites 0 Cited by

Patent Information

Application Number
CN202610398732.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-03-30
Publication Date
2026-06-23

AI Technical Summary

Technical Problem

Existing anti-B7-H3 antibodies have problems in clinical applications, such as incomplete sequence disclosure, large differences in reactivity across species, inconsistent detection platforms, and insufficient enhancement of T cell killing ability, lacking standardization and multifunctionality.

Method used

Two representative monoclonal antibodies, 2B2-1 and 5G4-2, were developed. Their heavy and light chain variable region sequences were identified, and their high specificity and high affinity in flow cytometry, immunohistochemistry, ELISA, and T cell killing assays were verified. They are suitable for multiple detection platforms and enhance the killing effect of T cells on CD276-overexpressing tumor cells.

Benefits of technology

It provides antibodies with well-defined sequences, high specificity and affinity, suitable for multiple detection platforms, and enhances the killing ability of T cells against CD276-overexpressing tumor cells, providing an excellent antibody backbone for further development of diagnostic reagents and therapeutic drugs.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicine and tumor immunotherapy, and particularly relates to a monoclonal antibody aiming at an immune checkpoint molecule CD276 (B7-H3) and application of the monoclonal antibody. According to the invention, immunization and screening work is carried out around a human CD276 antigen, two representative monoclonal antibodies, namely 2B2-1 and 5G4-2, are screened from a plurality of obtained candidate antibodies, and nucleotide and amino acid sequences of heavy chain and light chain variable regions are determined; the expression of the monoclonal antibody in flow cytometry, T cell killing experiments, immunohistochemistry, ELISA (Enzyme-Linked Immunosorbent Assay) and surface plasmon resonance (Biacore) affinity detection is systematically evaluated. Experimental results show that the antibody can specifically recognize and combine CD276, efficiently distinguish CD276 high-expression and low-expression cells, enhance the killing activity of T cells to CD276 high-expression tumor cells in an in-vitro co-culture system, and provide an excellent antibody skeleton for subsequent construction of diagnostic kits, ADC drugs or bispecific antibodies and the like.
Need to check novelty before this filing date? Find Prior Art